Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential edaravone dexborneol injection followed by Y-2 sublingual tablets in acute ischemic stroke (Phase III)
CTR20234056Phase 3Active
- Sponsor
- Yinuoyi Biotech
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ischemic stroke comparing Sequential edaravone dexborneol + Y-2 sublingual tablets with Placebo sequential regimen (2 arms). Primary endpoint: Proportion of patients with mRS ≤ 1 at day 90. Started Dec 2023; status: active.
02
Drugs
edaravone dexborneol
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on CTR20234056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20234056.